Results 161 to 170 of about 118,577,238 (222)

Early-Season Detection of Influenza A(H3N2) Subclade K in Wastewater, Colorado, USA, 2025-2026. [PDF]

Emerg Infect Dis
Hetherington-Rauth MC, Nguyen V, Washeleski E, Vital KC, Lequia G, Aragon D, Alden NB, Weisbeck K, Bankers L, Rossheim A, Wheeler A, Matzinger SR.   +11 more
europepmc   +1 more source

Antiviral Resistance Associated With Multiple Mutations Occurring in Seasonal Influenza A(H3N2) Virus in a Patient Treated With Oseltamivir. [PDF]

Clin Case Rep
Hussain S, Guo C, Deng YM, Deshpande N, Chanthalavanh P, Spirason N, Burmas L, Peck H, Gardiner BJ, Barr IG.   +9 more
europepmc   +1 more source

Genomic Surveillance and Phylogenetic Analysis of Influenza A(H1N1) pdm09 and A(H3N2) Viruses in Burkina Faso, 2024. [PDF]

Adv Virol
Sawadogo C, Cissé A, Gouba N, Ilboudo AK, Savadogo M, Lingani M, W O Kabore B, Tarnagda G, Ouoba JB, Dama E, Dahourou A, Gampini S, Ouedraogo H, Tarnagda Z.   +13 more
europepmc   +1 more source

Intranasal delivery of a COBRA-based protein vaccine adjuvanted with c-di-AMP enhances breadth of protective immune responses against seasonal influenza viruses. [PDF]

Front Immunol
Caetano CCS, Prots DA, Thomas MH, Micallef DR, Richardson RA, Ross TM.   +5 more
europepmc   +1 more source

Sex and age differences in antibody responses to seasonal influenza vaccination are mediated by estrogenic upregulation of NF-κB and TNF signaling in B cells. [PDF]

mBio
Park H-S, Yin A, Zhou W, Wenstedt EFE, Jedlicka A, Dziedzic A, Werner A, Fenstermacher KZJ, Li H, Shea PJ, Lee JS, Gearhart P, Maul RW, Van Den Berg SAA, Rothman RE, Ji H, Leng SX, Pekosz A, Klein SL.   +18 more
europepmc   +1 more source

Hemagglutination-inhibition and microneutralization antibody titers as mediators of protection for cell-based and recombinant influenza vaccines. [PDF]

NPJ Vaccines
Zhong S, Lim WW, Ho F, Gaglani M, Naleway AL, Dawood FS, Levine MZ, Sumner K, Flannery B, Cowling BJ.   +9 more
europepmc   +1 more source

Adaptive Advantage of the Emerging Seasonal Influenza A (H3N2) Subclade K: Enhanced Receptor Binding Capacity and Immune Escape Potential. [PDF]

MedComm (2020)
Zhang L, Zhao T, Pan X, Feng Z, Zhang D, Wang Q, Yang P.   +6 more
europepmc   +1 more source

Towards anti-influenza nasal sprays: infection models and opportunities to reduce animal testing. [PDF]

Npj Viruses
Thomas J, Nilius CA, Matis L, Schnur S, Himmelstein A, Novak AW, Kurreck J, Hittinger M, Lauster DC.   +8 more
europepmc   +1 more source

mRNA-based seasonal influenza vaccines: an overview of immunogenicity, efficacy, and safety. [PDF]

Front Immunol
Domnich A, Orsi A.
europepmc   +1 more source